DocDollars

Alnylam Pharmaceuticals Inc.

MA · United States · Reporting entity ID 100000481817

Total reported 2019–2025
$197.5M
#60 of 2,960 reporting companies — 0.2% of all reported industry payments
$40.3M in general payments across 98,231 records, plus $157.2M in research funding across 81,050 records.

How it breaks down

General payments $40,260,635
Research funding $157,241,978

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Alnylam Pharmaceuticals Inc. reported $197.5M to US doctors and teaching hospitals from 2019 to 2025, ranking #60 of 2,960 reporting companies. 80% of that was research funding and 20% general payments such as consulting, speaking, food and travel. 98,231 general payment records and 81,050 research records were filed.

Common questions about Alnylam Pharmaceuticals Inc.

How much has Alnylam Pharmaceuticals Inc. paid US doctors?

Alnylam Pharmaceuticals Inc. reported $197,502,613 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $40,260,635 in general payments, $157,241,978 in research funding.

How does Alnylam Pharmaceuticals Inc. rank among drug and device companies?

It ranks #60 of 2,960 reporting entities by total reported value, about 0.2% of all industry payments in the dataset.

Does a payment from Alnylam Pharmaceuticals Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.